SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC
What is next for radiopharmaceuticals in NETs?
While early-phase findings confirm the efficacy and mild toxicity of radiopharmaceuticals, patient selection and logistical issues limit their integration into broad clinical practice
Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell carcinoma
In a phase III trial, lower doses of adjuvant radiotherapy plus docetaxel were associated with reduced toxicity and need for percutaneous endoscopic gastrostomy, with an impact on quality of life
Cancer Control Principles
Hypofractionation may help reduce the impact of radiotherapy on the environment
Recent research suggests a substantial reduction in greenhouse gas emissions with de-escalation per cancer patient
Neoadjuvant pembrolizumab plus chemotherapy increases pathological complete response in high-risk early breast cancer
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Pre-operative immunoradiation shows clinical benefit in patients with high-risk, early-stage breast cancer
Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy
Radiopharmaceuticals boost the efficacy of androgen-receptor pathway inhibitors in metastatic castration-resistant prostate cancer
The first results from two phase III studies of Ra-223 and 177Lu-PNT2002 may help to decipher their role in the treatment of patients with mCRPC
Neoadjuvant chemoradiotherapy has no role in the treatment of operable gastric cancer
Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients